Neesgaard Bastian, Ruhwald Morten, Weis Nina
Bastian Neesgaard, Nina Weis, Department of Infectious Diseases, Copenhagen University Hospital Hvidovre, 2650 Hvidovre, Denmark.
World J Hepatol. 2017 May 18;9(14):677-688. doi: 10.4254/wjh.v9.i14.677.
To investigate interferon-γ-inducible protein-10's (IP-10) potential to anticipate rapid (RVR)- and sustained virological responses (SVR) to chronic hepatitis C (CHC) treatment.
We included case series examining RVR or SVR in relation to 24 or 48 wk treatment for CHC, in patients treatment free for at least six months, with genotype 1 or 4, and in relation to 24 wk treatment for genotype 2 and 3, with pegylated interferon in combination with ribavirin. Patients had to have both a baseline IP-10 level as well as a hepatitis C virus (HCV)-RNA determination 4 wk after treatment initiation or 24 wk after end of treatment. Studies including patients with liver diseases other than CHC, human immunodeficiency virus-infection, treatment with immunosuppresents or cytostatica, alcohol dependency or active intravenous drug-use were excluded. We found 81 articles by searching the MEDLINE and EMBASE databases. Eight studies were eligible for inclusion. Their quality were assesed using an 18 point checklist for case series, developed using a modified Delphi technique. Information was extracted from the articles, and no raw data was requisitioned. The review protocol was registered at the International Prospective Register of Systematic Reviews (reg. number: CRD42014008736).
Three studies reported on baseline IP-10 level in association with RVR. A signigficant association was found for HCV genotype 1 infection by two studies. Only two studies reported on HCV genotype 4 infected and genotype 2 and 3 infected patients, respectively. A trend was seen for an association between RVR and baseline IP-10 for genotype 4, while no association was found for genotype 2 and 3. Seven studies provided information regarding baseline IP-10 and SVR. Following the pattern regarding rapid virological response all five studies examining SVR in relation to baseline IP-10 levels for HCV, genotype 1 infected patients showed a significant association. Likewise a significant association was seen for HCV, genotype 4 infected, while no association was found for HCV, genotype 2 and 3 infected. Though only two studies examined the assosiation for HCV genotype 4 infected and HCV genotype 2 and 3 infected respectively.
We found indications of a possible association between baseline IP-10 level and virological responses in patients with CHC genotype 1 and 4.
研究干扰素γ诱导蛋白10（IP - 10）预测慢性丙型肝炎（CHC）治疗快速病毒学应答（RVR）和持续病毒学应答（SVR）的潜力。
我们纳入了病例系列研究，这些研究涉及CHC患者接受24周或48周治疗后的RVR或SVR情况，患者至少六个月未接受治疗，基因型为1或4，以及基因型2和3患者接受24周聚乙二醇干扰素联合利巴韦林治疗后的情况。患者必须有基线IP - 10水平以及治疗开始后4周或治疗结束后24周的丙型肝炎病毒（HCV）-RNA测定值。排除包括患有CHC以外肝脏疾病、人类免疫缺陷病毒感染、接受免疫抑制剂或细胞抑制剂治疗、酒精依赖或活跃静脉吸毒的患者的研究。通过检索MEDLINE和EMBASE数据库，我们找到了81篇文章。八项研究符合纳入标准。使用通过改良德尔菲技术制定的18点病例系列检查表评估其质量。从文章中提取信息，未索取原始数据。该综述方案已在国际前瞻性系统评价注册库注册（注册号：CRD42014008736）。
三项研究报告了基线IP - 10水平与RVR的关联。两项研究发现HCV基因型1感染存在显著关联。仅两项研究分别报告了HCV基因型4感染以及基因型2和3感染的患者。对于基因型4，RVR与基线IP - 10之间存在关联趋势，而对于基因型2和3未发现关联。七项研究提供了关于基线IP - 10和SVR的信息。遵循快速病毒学应答的模式，所有五项研究在检查HCV基因型1感染患者的SVR与基线IP - 10水平的关系时均显示出显著关联。同样，HCV基因型4感染也显示出显著关联，而HCV基因型2和3感染未发现关联。不过仅两项研究分别检查了HCV基因型4感染以及HCV基因型2和3感染的关联情况。
我们发现CHC基因型1和4患者的基线IP - 10水平与病毒学应答之间可能存在关联迹象。
